Riliprubart Earns Orphan Drug Designation in the US for Antibody-mediated Rejection in Solid Organ Transplantation This designation reflects Sanofi’s commitment to addressing a critical unmet need in ...

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

Sanofi (NASDAQ: SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

In June 2025, Sanofi announced that its investigational drug riliprubart received orphan drug designation from the US FDA for treating antibody-mediated rejection in solid organ transplantation, ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

赛诺菲免疫学全球研发负责人Alyssa Johnsen博士对此表示：“这一认定是对riliprubart解决关键医疗空白潜力的重要认可。 我们将全力加速其临床开发进程，目标是尽早为饱受AMR折磨的移植患者带来变革性的治疗方案。” ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 ...

SEALSQ Corp (NASDAQ: LAES) ('SEALSQ' or 'Company'), a company that focuses on developing and selling Semiconductors, PKI, and ...